News

Stories

See all

Naming a New Drug During a Pandemic

View Story

Updates: Lilly's Global COVID-19 Response

View Story

Lilly's COVID-19 Science Leads to a Second FDA Emergency Use Authorization

View Story

Time to Tear Down the Rebate Wall

View Story

When the World Called for Help with COVID-19, We Were Ready

View Story

Dave Ricks Shares About Lilly's FDA Emergency Use Authorization for a Neutralizing Antibody

View Story


Press Releases

See all

Lilly announces 650,000 additional doses of neutralizing antibody bamlanivimab (LY-CoV555) purchased by U.S. government to treat COVID-19

December 2, 2020

Tags |  Product

INDIANAPOLIS , Dec. 2, 2020 /PRNewswire/ -- The U.S. government has purchased 650,000 additional doses of Eli Lilly and Company's (NYSE: LLY) neutralizing antibody bamlanivimab (LY-CoV555) 700 mg. The purchase agreement is for $812.5 million and the doses will be delivered through January 31, 2021




Lilly to Participate in Evercore ISI 3rd Annual HealthCONx Conference

November 24, 2020

Tags |  Financial

INDIANAPOLIS , Nov. 24, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Evercore ISI 3 rd Annual HealthCONx Conference on Tuesday, December 1, 2020 . Michael Mason , Lilly senior vice president and president of Lilly Diabetes and Connected Care, will participate in a




Lilly's neutralizing antibody bamlanivimab (LY-CoV555) receives interim authorization from Health Canada as a treatment for COVID-19

November 20, 2020

Tags |  Product

- Bamlanivimab emerged from collaboration between Lilly and Vancouver-based AbCellera INDIANAPOLIS , Nov. 20, 2020 /PRNewswire/ -- Health Canada today granted authorization under the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 for the use




Lilly and Precision BioSciences Announce Genome Editing Research Collaboration and License Agreement

November 20, 2020

Tags |  Corporate

Research collaboration using ARCUS genome editing technology will initially include three gene targets, with right to select three additional gene targets; lead program focused on Duchenne Muscular Dystrophy   Precision will receive $100 million cash upfront and an equity investment by Lilly of $35